

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

MEC-1

RRID:CVCL_1870

Type: Cell Line

Proper Citation

RRID:CVCL_1870

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1870

Proper Citation: RRID:CVCL_1870

Description: Cell line MEC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Chronic lymphocytic leukemia

Defining Citation: [PMID:10071128](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:22460905](#), [PMID:23297799](#), [PMID:25162594](#), [PMID:25877200](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MEC-1

Synonyms: MEC1

Cross References: BTO:BTO_0005913, CLO:CLO_0037181, EFO:EFO_0002231, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03471015, BioSample:SAMN10989555, cancercellines:CVCL_1870, Cell_Model_Passport:SIDM00001, ChEMBL-Cells:ChEMBL4482990, ChEMBL-Targets:ChEMBL4483257, Cosmic:1762462, DepMap:ACH-000405, DSMZ:ACC-497, DSMZCellDive:ACC-497, EGA:EGAS00001000978, GDSC:1330943, GEO:GSM887305,

GEO:GSM888381, GEO:GSM1374667, GEO:GSM1670091, IARC_TP53:28260, IGRhCellID:MEC1, LiGeA:CCLE_715, LINCS_LDP:LCL-1089, PharmacDB:MEC1_911_2019, Progenetix:CVCL_1870, PubChem_Cell_line:CVCL_1870, Wikidata:Q54904995

ID: CVCL_1870

Record Creation Time: 20220427T220800+0000

Record Last Update: 20260913T004842+0000

Ratings and Alerts

No rating or validation information has been found for MEC-1.

No alerts have been found for MEC-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 207 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Dell'Aversana C, et al. (2026) UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. Journal of hematology & oncology, 19(1).

Wang X, et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell reports. Medicine, 7(7), 102885.

Barozzi D, et al. (2025) Dynamic stimulation promotes functional tissue-like organization of a 3D human lymphoid microenvironment model in vitro. Cell reports methods, 5(7), 101105.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Mamidi MK, et al. (2025) Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(3), 588.

Thomas BJ, et al. (2025) DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. Cancer immunology research, 13(11), 1798.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Ron?evi? T, et al. (2023) Relating Molecular Dynamics Simulations to Functional Activity for Gly-Rich Membranolytic Helical Kiadin Peptides. *Pharmaceutics*, 15(5).

Dong Z, et al. (2023) Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies. *Blood advances*, 7(6), 918.

Hu X, et al. (2023) CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia. *Experimental hematology & oncology*, 12(1), 6.

Sordo-Bahamonde C, et al. (2023) BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. *Cancer immunology, immunotherapy : CII*, 72(7), 2529.

Sher S, et al. (2023) VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. *Leukemia*, 37(2), 326.

Hing ZA, et al. (2023) Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation. *Nature communications*, 14(1), 97.

Boronat-Toscano A, et al. (2023) Smoking Suppresses the Therapeutic Potential of Adipose Stem Cells in Crohn's Disease Patients through Epigenetic Changes. *Cells*, 12(7).

Timofeeva N, et al. (2023) Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. *Frontiers in oncology*, 13, 1161254.

Capolla S, et al. (2023) Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models. *Frontiers in immunology*, 14, 1200310.

Kreer C, et al. (2023) Probabilities of developing HIV-1 bNAbs sequence features in uninfected and chronically infected individuals. *Nature communications*, 14(1), 7137.

Ecker V, et al. (2023) Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. *Cell reports*, 42(10), 113017.

Matis S, et al. (2022) LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells. *Hematological oncology*, 40(1), 40.

Guzelj S, et al. (2022) Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators. *Journal of medicinal chemistry*, 65(22), 15085.